On the August 9, 2018, Sydney Vital teamed up with The Unicorn Foundation to host the 2018 Neuroendocrine Tumour Q&A Session. The session saw over 100 attendees come together to hear about what’s new in Neuroendocrine Tumours and why research plays a vital role in patient outcomes.
The expert panel consisted of medical specialists, patient advocates and patients who each gave their unique perspective about people who live in our community with Neuroendocrine Tumours. Among the expert panel members were A/Prof Nick Pavlakis, Prof Alexander Engel, A/Prof Paul Roach, A/Prof Mustafa Khasraw, Dr J Parikh, Dr John Leyden, Meredith Cummins and Katie Golden.
Patient stories are one of the most powerful ways of raising awareness about this rare group of tumours. Katie Golden, who was diagnosed with NET cancer in 2011, represented people across NSW and Australia who have been diagnosed with the disease as she bravely shared her story.
There were some great questions from our audience and the panel members gave informative responses on a number of topics including patient treatment options and clinical trials. One of the topics that stood out was just how advanced Australia is in the treatment of Neuroendocrine Tumours. John Leyden from The Unicorn Foundation commented that ‘Australia is spearheading when it comes to NETs, we have a community of passionate and dedicated doctors as well as patient advocates.’
We’d like to thank our Q&A Panel Members who made this event a huge success. We hope that we raised some knowledge about what our fantastic team in NSW are doing towards finding a cure for and treating Neuroendocrine Tumours.
Post a comment